14:00 – 14:25
ROOM A | Opening lecture
Chair: João Morais
• ATHEROTHROMBOSIS: a contemporary overview and a glimpse into the future | Lars Wallentin

14:30 – 16:00
ROOM A | New avenues for combating atherothrombosis
Chairs: Carlos Aguiar, Robert Storey

• The era of personalized medicine on antithrombotics | Carlo Patrono
• LDL-cholesterol and beyond | Carlos Aguiar
• New developments in P2Y12 blockade | Robert Storey
• Repurposing old drugs targeting inflammation | Bruna Gigante

ROOM B | New avenues for combating venous thromboembolism
Chairs: Lucia Mazzolai, Bianca Rocca

• Pulmonary embolism: for whom revascularization is an option? | Marianne Brodmann
• Deep vein thrombosis: for whom revascularization is an option? | Oliver Schlager
• Personalized treatment of VTE in non cancer patients | Rupert Bauersachs
• Personalized treatment of VTE in cancer patients | Cecilia Becattini

16:00 – 16:30 | Posters & coffee break

16:30 – 17:55
ROOM A | Challenges in antithrombotic therapy in special populations
Chairs: Daniel Caldeira, Christine Espinola-Klein

• Cardiogenic shock | Diana Gorog
• Polyvascular atherosclerotic disease | Victor Aboyans
• The elderly and the very elderly | Andrea Rubboli
• Chronic kidney disease | Christian Torp-Pedersen

ROOM B | Coronary Microcirculatory Dysfunction
Joint Session with the ESC WG on Coronary Pathophysiology, Microcirculation
Chairs: Teresa Padró, Jolanta Siller Matula

• Role of coronary microvascular dysfunction in cardiovascular disease | Dirk Duncker
• Ischemic heart disease in women: Risk Factors and Pathophysiology | Teresa Padró
• How to address the no-reflow phenomenon in ACS | Jolanta Siller Matula
• INOCA, a permanent challenge to our knowledge | Nuno Dias Ferreira

18:00 – 18:25
ROOM A | Fontaine Lecture
Chairs: Victor Aboyans, Gemma Vilahur

• Global Burden PAD | Gerry Fowkes

18:30 – 19:15
ROOM A | Industry Satellite Symposium – Amarin
One step further in reducing established cardiovascular disease risk: targeting atherothrombosis after REDUCE-IT
Chair: João Morais

• Established CVD and atherothrombosis: how did we get here and how can we get out | Francisco Araújo

• Icosapent Ethyl, a new player in reducing atherothrombotic risk? | Victor Aboyans

19:15 – 20:15
Welcome Reception

08:00 – 08:55
ROOM A | Case-based session
Organised by the ESC WG on Thrombosis Young Researchers
Chairs: Andrea Rubboli, Christina Christersson
Discussants: Eduardo Infante de Oliveira, Diana Gorog

CC3 | Coronary Subclavian Steal Syndrome: an unusual cause of Acute Myocardial Infarction | Ana Isabel Pinho
CC4 | Percutaneous Patent Foramen Ovale Closure after a Thrombotic Storm: A Case Report | David Sá-Couto
CC17 | A catastrophic case of ischemic stroke and acute myocarditis in a young patient following mRNA COVID-19 vaccination: coincidence or consequence? | Jéni Quintal
CC31 | Active gastrointestinal bleeding during STEMI: a management dilemma | Vanessa Lopes

ROOM B | Oral Presentations | Thrombosis and antithrombotic strategies I
Chairs: Ingebjorg Seljeflot, João Morais

OP82 | Pre-treatment with Dual Antiplatelet Therapy in NSTE-ACS: not always, not ever | António Rocha de Almeida
OP83 | Coronary Aspiration Thrombectomy: bringing back the old kid on the block | António Rocha de Almeida
OP107 | Achieving higher efficacy without compromising safety with Factor XI inhibitors versus low-molecular-weight heparin for the prevention of venous thromboembolism in major orthopedic surgery | João Presume
OP112 | Treatment of pulmonary embolism after paradoxical stroke | Mariana Martinho
OP114 | Small-bore aspiration thrombectomy versus catheter-directed thrombolysis in intermediate-high risk acute Pulmonary Embolism | Mariana Martinho

ROOM C | Oral Presentations | Hematological biomarkers and prognostic implications
Chairs: Rory Koenen, Heleen Van Beusekom

OP32 | The interplay between VWF, ADAMTS13 and TSP1, and their relation to clinical endpoints | Ellen Mathea Kirsch Warlo
OP41 | High plasma von Willebrand factor concentration is associated with the development of bleeding complications in patients with polyvascular disease receiving multicomponent antithrombotic therapy | Elena Krivosheeva
OP55 | Is White Blood Count a Good Marker to Coronary Disease Risk? | Débora Sá
OP56 | Elevated White Blood Cells Count and C-Reactive Protein as markers for coronary heart disease prognosis | Débora Sá
OP68 | Plasma fibrinogen independently predicts hypofibrinolysis in severe COVID-19 | Diana Schrick

09:00 – 10:30
ROOM A | Unrevealing the complexity of thrombosis in ACS
Chairs: Lina Badimon, Bruna Gigante

Cardiac benefits of P2Y12 inhibitors beyond their antiplatelet properties | Gemma Vilahur
Monocyte and macrophage subsets in coronary artery disease and beyond | Johann Wotja
Epigenetics in atherothrombosis | Manuel Mayr
Factor Xa and platelet activation | Daniel Caldeira

ROOM B | New concepts on old vascular disease
Chairs: Oliver Schlager, José Rodriguez Palomares

• Clinical Case | Giacomo Buso
• Fibromuscular Disease: no more reason to ignore it | Alexandre Persu
• Clinical Case | Giacomo Buso
• Aortic tortuosity: assessment and clinical consequences | Roland Van Kimmenade

10:30 – 11:00 | Posters & coffee break

11:00 – 12:25
ROOM A | Diabetes: targeting the increase in cardiovascular risk
Chairs: Carlo Patrono, Pedro Matos

• Myocardial Revascularization: A permanent challenge in Diabetes | Eduardo Infante de Oliveira 
Managing glucose metabolism: does glycemia still matter? | Ramzi Ajjan
How to stratify risk in diabetic patients | Pedro Matos
Platelet inhibition | Bianca Rocca

ROOM B | Lower Extremity Artery Disease: improved management for better outcome
Chairs: Marco De Carlo, Frank Vermassen

Optimal pharmacotherapy | Tristan Mirault
Best Exercise training modalities | Lucia Mazzolai
Endovascular revascularization? What we know and where we are heading to | Frank Vermassen
Biomarkers in LEAD | Christian Heiss

12:30 – 13:45
ROOM A | Oral Presentations | Insights on vascular biology and disease
Chairs: Roland van Kimmenade, Tristan Mirault

OP6 | Postoperative Myocardial Injury due to Platelet Reactivity in Patients undergoing Vascular Surgery | Kai Zheng
OP48 | Sex-based differences in patients with peripheral arterial disease admitted for acute coronary syndrome – Insights from a multicentre national registry | Margarida Cabral
OP75 | Impact of thoracic aortic calcification measured by computed tomography in clinical outcomes in patients undergoing cardiac surgery | Margarida Cabral
OP89 | Vascular access computed tomography angiography-derived iliofemoral calcium volume in the evaluation of vascular and bleeding complications after transfemoral TAVI | Mariana Ribeiro Silva
OP91 | Valve-in-valve TAVI for treatment of degenerated surgical aortic bioprosthesis | Mariana Ribeiro Silva
OP121 | Aortic stiffness descriptors by cardiac magnetic resonance are correlated with mechanical testing of ex-vivo aortic aneurysms specimens | Aroa Ruiz Muñoz
OP125 | Relation of non-invasively measured ankle-brachial index and pulse-wave velocity towards all-cause mortality in unselected emergency department patients – a prospective cross-sectional study | Oliver Schlager

ROOM B | Oral Presentations | Basic knowledge to understand thrombosis
Chairs: Gemma Vilahur, Johann Wotja

OP3 | Growth differentiation factor-15 and bleeding complication risk in patients with coronary artery disease, receiving combined antithrombotic therapy | Elena Krivosheeva
OP19 | Bi-directional cross talk between coagulation, fibrinolysis and inflammatory pathways in patients with ST-segment elevation myocardial infarction | Rahim Kanji
OP46 | The effect of covid-19 vaccine on the endothelial function | Ahmed Makni
OP90 | Pleiotropic effect of antiplatelet ticagrelor: expression of CYP4F2 in HUVEC and HepG2 | Ieva Ciapiene
OP93 | Assessing different noncoding RNAs as markers of platelet reactivity | Clemens Gutmann
OP105 | Endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure | Tasnim Mohaissen
OP64 | Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention | Shqipdona Lahu

14:10 – 15:40
ROOM A | Antithrombotics in non-coronary interventions
Chairs: Christopher Twine, Tobias Geisler

TAVI | Jurrien Ten Berg
Left Atrial Appendage and PFO | Tobias Geisler
Peripheral revascularization | Marco De Carlo
Aortic endovascular therapy | Christopher Twine

ROOM B | Platelets in atherosclerosis and vascular biology: beyond thrombosis
Joint Session with the ESC WG on Atherosclerosis and Vascular Biology
Chairs: Marie-Luce Bochaton-Piallat, Gemma Vilahur

Platelet-derived extracellular vesicles, chemokines and cell adhesion molecules in atherosclerosis | Rory Koenen
Platelet-derived EVs as biological players after myocardial infarction – good or bad? | Christina Christersson
• The (not so) smooth muscle cell in atherosclerosis | Marie-Luce Bochaton-Piallat
Vascular injury and repair and the journey of microthrombi following mechanical thrombectomy | Heleen Van Beusekom

15:40 – 16:00 | Posters & coffee break

16:00 – 17:25
ROOM A | Novel approaches in Lower Extremity Artery Disease (LEAD)
Joint Session with the European Society of Vascular Medicine
Chairs: Oliver Schlager, Victor Aboyans

Supervised exercise training in LEAD: alternative or adjuvant to revascularization? | Christine Espinola-Klein
Interventional management of calcified arterial lesions | Marianne Brodmann
Regenerative therapy in no-option chronic limb threatening ischemia | Juraj Madaric
Air pollution and Critical Limb Ischemia | Jill Belch

ROOM B | Strategies to prevent the continuum in CV Risk
Chairs: Francisco Araújo, Tobias Geisler

Effects of exercise training on atherothrombotic risk | Ingebjorg Seljeflot
The polypill in primary and secondary prevention. Where do we stand? | Diederick Grobbee
Preventive strategies in patients with CKD | Rui Baptista
Association between influenza vaccination and cardiovascular diseases | Tobias Geisler

17:30 – 17:55
ROOM A | Steen Husted Lecture
Chairs: Bianca Rocca, Lucia Mazzolai
• Current advances in ischemic stroke research and therapies | Heleen Van Beusekom

18:00 – 18:30
ROOM A | ESC WG on Thrombosis General Assembly
• General information to members of the Working Group (ongoing and upcoming activities)

08:00 – 08:55
ROOM A | Moderated posters
Chairs: Heleen Van Beusekom, Marco de Carlo

PO12 | Premature myocardial infarction: a decade-long analysis of patients admitted to a single-center coronary care unit | Vanessa Lopes
PO106 | Can we optimize d-dimer cut off value to predict pulmonary embolism in covid-19 patients? | Rafaela Fernandes
PO52 | The Influence of the CYP2C9 polymorphisms on the treatment with clopidogrel: combined data from the POPular Genetics & POPular AGE trials | Wout van den Broek
PO109 | Prognostic value of white blood cell count variation during in-hospital stay in STEMI patients: Insights from SCALIM Registry | Pierre Chenard
PO122 | Predicting the rate of progressive dilation by wall shear stress in bicuspid aortic valve patients | José Rodriguez-Palomares

ROOM B | Oral Presentations | Thrombosis and antithrombotic strategies – II
Chair: Diana Gorog

OP34 | A Case Series of patients with Pulmonary Embolism during post COVID-19 period | Elena Leonidou
OP53 | Dose-related preprocedural patency of the infarct-related artery after zalunfiban (RUC-4) administration upon arrival at the catheterization laboratory in ST-elevation myocardial infarction: insights from the phase IIa study | Sem A.O.F. Rikken
OP67 | Thrombotic Events in COVID-19 Patients Admitted at Chinese General Hospital and Medical Center | Joel Santos
OP79 | Quality of life in patients after pulmonary embolism. Correlation with echocardiographic and biochemical parameters | Olga Kardakari
OP126 | NOACs safety and efficacy in Adult Congenital Heart Disease | Cátia Oliveira

ROOM C | Oral Presentations | Brief tips useful for the clinicians
Chairs: Andrea Rubboli, Bruna Gigante

OP69 | Chronotropic incompetence: still a suitable indicator? | Isabel Cruz
OP81 | A STEMI case with sub-occlusive lesion and high thrombotic burden – discussing a tailored approach | Maria Rita Lima
OP84 | Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention | Nadir Elamin
OP96 | Impact of inflammatory and hematological factors to the left ventricule function, remodeling, and  clinical outcomes after the first myocardial infarction | Nina Korac
OP10 | Pharmacological therapy in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): long-term prognosis | Vanessa Lopes

09:00 – 10:30
ROOM A | Update on antithrombotic strategies
Chairs: Sigrun Halvorsen, João Morais

Antithrombotic strategies after AMI | Cristina Gavina
Dual pathway in atherothrombotic disorders | João Morais
• Management of anti-thrombotic treatment in patients undergoing non-cardiac surgery | Sigrun Halvorsen
• Ongoing preclinical and clinical trials on FXIa and FXIIa | Hugo ten Cate

ROOM B | Aorta – What’s new since the 2014 guidelines? 
Chairs: Luís Mendes Pedro, Martin Czerny

Genetics of Aortic Diseases | Julie Debacker
New multimodality imaging techniques of the thoracic and abdominal aorta | José Rodriguez Palomares
Type B aortic dissection: when to intervene | Martin Czerny
Ruptured AAA: from prevention to intervention | Frank Vermassen

10:30 – 11:00 | Posters & coffee break

11:00 – 12:25
ROOM A | Optimizing outcomes in Vascular Surgery
Joint Session with the European Society of Vascular Surgery
Chairs: Lucia Mazzolai, João Morais

• Should we continue to screen cardiac diseases prior to peripheral revascularization? | Marco De Carlo
• Optimal medical treatment of candidates to Vascular Surgery in 2022 | Christopher Twine
• Peri-operative management of antithrombotic therapies | Christine Espinola-Klein
• Follow-up after vascular intervention | Christian Heiss

ROOM B | Predictive Biomarkers
Chairs: Bruna Gigante, Cristina Gavina

Biomarkers of bleeding | Agneta Seigbahn
Biomarkers of arterial thrombosis | Lina Badimon
Biomarkers of fibrinolysis | Diana Gorog
Biomarkers of venous thrombosis | Arina ten Cate-Hoek

12:30 – 13:00
ROOM A | Closing session

• Poster awards and closure of conference | João Morais, Andrea Rubboli, Oliver Schlager

This International Conference is supported by Bayer, Daiichi-Sankyo, Tourism of Lisbon, Amarin, AstraZeneca, Evigation and Mobit in the form of an educational grant.

The scientific programme has not been influenced in any way by its sponsors.

Download Scientific Programme